TCR2 raises $75M in IPO

TCR2 Therapeutics Inc. (NASDAQ:TCRR) raised $75 million in an IPO priced Feb. 13. The immuno-oncology company priced 5 million shares at $15, the midpoint of its proposed range of $14-$16. The price valued TCR2 at $347.8 million.

TCR2 is developing T cell receptor fusion constructs (TRuCs), which comprise tumor antigen recognition domains fused to TCRs. The company thinks its TRuCs could have greater activity against solid tumors than CAR T therapies, and broader applicability than TCR therapies (see "TRuCs vs. CARs")...